Low-dose brimonidine combinations and uses thereof
Low-dose brimonidine combined with a second glaucoma drug or histamine antagonist/NSAID addresses the limitations of existing treatments by enhancing IOP reduction and minimizing side effects, improving treatment efficacy and compliance.
Patent Information
- Application Number
- JP2024137601
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-01-24
- Filing Date
- 2024-08-19
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing glaucoma treatments suffer from limited effectiveness in lowering intraocular pressure (IOP) and cause side effects such as fatigue, sedation, lid damage, and red eyes, with many patients requiring multiple drugs and experiencing non-compliance due to side effects.
A combination of low-dose brimonidine (0.01% to 0.050% w/v) with a second glaucoma drug or a histamine antagonist/NSAID reduces IOP and alleviates side effects like redness and swelling by minimizing alpha 1 agonist activity and vascular leakage.
The combination provides enhanced IOP reduction and reduces side effects, improving patient compliance by minimizing systemic and ocular side effects, and potentially reducing the frequency of administration.
Smart Images

Figure 2024164101000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to compositions containing low dose brimonidine and either a second glaucoma drug, an antihistamine, or a nonsteroidal anti-inflammatory drug.The present invention further relates to methods of treating glaucoma or allergies or reducing inflammation by administering the compositions of the present invention. [Background technology]
[0002] Glaucoma is a multifactorial disease encompassing a range of conditions ranging from elevated intraocular pressure ("IOP") to reduced vascular perfusion of the optic nerve.
[0003] Although many factors have been emphasized as contributing to the cause of glaucoma, existing treatments for glaucoma have limited effectiveness in reducing IOP and / or are accompanied by some side effects such as fatigue, sedation, eyelid allergy, local allergy, and / or redness.More than 10% of glaucoma patients suffer from symptoms of hyperemia (i.e., red eyes).Due to side effects, another major problem in glaucoma therapy is the patient's compliance with medication as described above.
[0004] More than 40% of glaucoma patients require two or more drugs for satisfactory control of intraocular pressure. Of these, prostaglandins / prostanoids, including Xalatan® (latanoprost) (Xalatan is a registered trademark of Pfizer Health AB), Travatan® (travoprost) (Travatan is a registered trademark of Novartis AG) and Lumigan® (bimatoprost) (Lumigan is a registered trademark of Allergan, Inc.), are the leading drugs due to their significant reduction of IOP, typically more than 30% in ocular hypertensive eyes (21 mmHg or more), and their long-lasting improvement in uveoscleral outflow. To achieve maximum effectiveness, the two drugs should have different mechanisms of action.
[0005] Brimonidine, a known alpha-2 (α-2) adrenergic receptor agonist, is currently available in the form of 0.1%, 1.5% and 0.2% brimonidine tartrate under the trade name Alphagan® (Alphagan is a registered trademark of Allergan, Inc.). Brimonidine typically produces a moderate peak IOP reduction of about 20-25% in ocular hypertensive eyes and 6-18% in normotensive eyes (less than 21 mmHg). The peak effect of brimonidine is within 2 hours of instillation, the duration of action of brimonidine is typically less than 12 hours, and the moderate effectiveness of brimonidine usually requires dosing 2-3 times daily. Brimonidine is one of the major second-line agents that is roughly equivalent to other second-class glaucoma medications such as beta-blockers and carbonic anhydrase inhibitors, and its mechanism of inhibitory action in water complements the uveoscleral outflow enhancement of prostaglandins / prostanoids for significant additive benefit. Brimonidine 0.2% has been observed to provide an additional 1-2 mmHg reduction in IOP when used in combination with beta-blockers or carbonic anhydrase inhibitors, especially prostaglandins.
[0006] However, 0.15-0.2% brimonidine can induce substantial local side effects in 10-25% of users, such as conjunctival hyperemia (i.e., red eye), blepharitis, allergy, chemosis, conjunctival follicles, foreign body sensation, burning sensation, or blurred vision. These side effects have only been moderately ameliorated by recent brimonidine formulations, which have resulted in somewhat reduced concentrations with increased intraocular absorption at more alkaline pH (Alphagan®). In general, alpha-2 agonists, including brimonidine, its predecessor clonidine, and the more selective dexmedetomidine, are known to induce substantial systemic effects when absorbed into the circulation, specifically increasing fatigue, decreasing blood pressure (i.e., hypotension), and decreasing heart rate (i.e., bradycardia). Brimonidine, due to its relative alpha2 / alpha1 specificity (ratio of approximately 900:1), may still deliver alpha1 agonist activity into the eye where any induced ischemia could potentially accelerate optic nerve loss over the long term.
[0007] Thus, there is a need in the art for combination glaucoma treatments that reduce side effects while maintaining at least additive efficacy.
[0008] Allergic diseases are a major health problem worldwide. Moreover, the prevalence of allergic diseases is rising in most countries. The two main forms of allergies include allergic rhinitis and ocular allergy. An allergic reaction occurs, in part, when the immune system responds to the presence of an allergen and produces histamine. The histamine then develops the main symptoms of allergies, which include a "runny" or "itchy" nose, sneezing, "watery" eyes, and a scratchy throat.
[0009] In allergic rhinitis, an allergic reaction occurs in the nose. Histamine released in response to the reaction causes local vascular swelling, resulting in increased capillary pressure and increased capillary permeability. Both of these effects result in rapid fluid leakage into the nasal tissues, making the nasal lining swollen and secretory.
[0010] Ocular allergies or allergic conjunctivitis are often accompanied by allergic rhinitis in response to the release of histamine. Eye signs and symptoms of allergies include itching, redness, swelling, tearing, burning and stinging.
[0011] Ocular allergies are often treated with eye drops including Opcon-A® (0.02675% naphazoline hydrochloride and 0.315% pheniramine maleate; Opcon A is a registered trademark of Bausch & Lomb Incorporated), Naphcon-A® (0.025% naphazoline hydrochloride and 0.3% pheniramine maleate; Naphcon-A is a registered trademark of Alcon Research Ltd), and Vasocon® (0.05% naphazoline hydrochloride and 0.5% antazoline phosphate; Vasocon is a registered trademark of Novartis AG) and AIbalon™ (0.05% naphazoline hydrochloride; Albalon is available from Allergan Pharmaceuticals).
[0012] However, many of the antihistamines prescribed or administered to treat ocular allergies and / or allergic rhinitis treat the histamine-induced itching and discomfort, but do not completely relieve the associated symptoms, including swelling secondary to vascular leakage, and redness (red eye), which results in both residual discomfort and an unhealthy appearance.Therefore, there is a further need in the art for a combination of allergy treatments that provide greater relief of the associated symptoms, including red eye. Summary of the Invention
[0013] In one embodiment, the present invention is directed to an ophthalmic composition for the treatment of glaucoma comprising brimonidine at a concentration of about 0.01% to about 0.050% (w / v) and a second glaucoma medication.
[0014] In another embodiment, the invention is directed to a method of treating glaucoma comprising administering to a subject in need thereof a composition comprising brimonidine at a concentration of about 0.01% to about 0.050% (w / v) and a second glaucoma medication.
[0015] In another embodiment, the present invention is directed to a method of treating glaucoma that further provides for a reduction in red eye.
[0016] In another embodiment, the present invention is directed to a method of treating glaucoma that further provides for whitening of the eye.
[0017] In another embodiment, the present invention is directed to a method of treating glaucoma that further provides for reduced conjunctival swelling as well as reduced hyperemia and whitening of the eye.
[0018] In one embodiment, the present invention is directed to an ophthalmic composition for the treatment of allergies comprising brimonidine at a concentration of about 0.01% to about 0.050% (w / v) and a histamine antagonist.
[0019] In another embodiment, the present invention is directed to a method of treating an allergy comprising administering to a subject in need thereof a composition comprising brimonidine at a concentration of about 0.005% to about 0.050% (w / v) and a histamine antagonist.
[0020] In another embodiment, the present invention is directed to a method of treating allergies that further provides eye whitening and or reduced inflammation.
[0021] In another embodiment, the present invention is directed to an ophthalmic composition for reducing inflammation comprising about 0.005% to about 0.050% (w / v) brimonidine and an effective amount of a nonsteroidal anti-inflammatory drug ("NSAID").
[0022] In another embodiment, the present invention is directed to a method of reducing inflammation comprising administering to a subject in need thereof a composition comprising brimonidine and an NSAID at a concentration of about 0.005% to about 0.050% (w / v). [Brief description of the drawings]
[0023] [Figure 1]1 is a projected example of IOP reduction following administration of 0.005% Latanoprost (0 hours, open bars) and 0.03% Brimonidine and 0.005% Latanoprost (4, 6 and 8 hours, closed bars). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] The discovery of the present invention is that postcapillary venule leakage can be selectively reduced by low-dose brimonidine rather than alpha 1 vasoconstrictor.Without wishing to be bound by a particular theory, it is believed that alpha 1 agonists constrict larger vessels such as arterioles to a much greater extent than low-dose brimonidine.Constriction of larger vessels results in ischemia, and repeated use leads to inflammation and recurrent hyperemia.Leakage in postcapillary venules has been shown to be associated with a transient loss of endothelial VE-cadherin protein resulting in gap junctions, with leakage along postcapillary venule cell walls. However, it has been surprisingly discovered that constriction of small blood vessels, particularly the post-capillary venules, without ischemia with low-dose brimonidine reduces such leakage without ischemia with tetrahydrozaline, oxymetazoline, or other alpha 1 agonist constricting agents, and alleviates the clinical sequelae of redness and swelling and redness that are not completely alleviated in the presence of the ischemia, making the combination of low-dose brimonidine with an antihistamine particularly effective.
[0025] In particular, but not limited to, when used in combination with such glaucoma drugs, surface inflammation, swelling and redness are reduced.In addition, IOP is further reduced.The present invention has discovered that lower concentrations of brimonidine provide the IOP-lowering benefits of effective second drugs, but also potentially reduce optic nerve ischemia without the concomitant alpha 1 agonist activity of higher concentrations of brimonidine.
[0026] "Brimonidine" includes, but is not limited to, brimonidine salts and other derivatives, including, but not limited to, brimonidine tartrate, 5-bromo-6-(2-imidazolin-2-ylamino)quinoxaline D-tartrate, Alphagan® (Alphagan is a registered trademark of Allergan, Inc.), and UK14,304.
[0027] The term "glaucoma medication" or "second glaucoma medication" includes, but is not limited to, all medications used to treat glaucoma, including medications used to reduce intraocular pressure, except for brimonidine.
[0028] The term "histamine antagonist" includes any chemical that has been discovered to antagonize at least one histamine receptor, including histamine H1 and histamine H2.
[0029] The term "allergy" or "allergies" or "allergic response" refers to allergic rhinitis and / or ocular allergy. Allergic rhinitis is an allergic inflammation of the nasal passages with accompanying symptoms including, but not limited to, runny nose, nasal congestion, nasal itching, sneezing, and ocular pruritus. Ocular allergy is any allergic disease of the eye, including, but not limited to, seasonal / perennial allergic conjunctivitis, vernal catarrhal keratoconjunctivitis, giant papillary conjunctivitis, perennial allergic conjunctivitis, and atopic keratoconjunctivitis.
[0030] The term "pharmaceutically acceptable salts" is meant to include salts of active compounds prepared with relatively non-toxic acids or bases, depending on the specific substituents recognized for the compounds described herein.When the compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base in either anhydrous inert solvent or in a suitable inert solvent.Examples of pharmaceutically acceptable base addition salts include sodium salts, potassium salts, calcium salts, ammonium salts, organic amino salts, or magnesium salts, or similar salts.When the compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid in either anhydrous inert solvent or in a suitable inert solvent. Examples of pharma- ceutically acceptable acid addition salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, nitric acid, carbonic acid, monohydrogencarbonic acid, phosphoric acid, monohydrogenphosphoric acid, dihydrogenphosphoric acid, sulfuric acid, monohydrogensulfuric acid, hydroiodic acid, or phosphorous acid, as well as salts derived from relatively non-toxic organic acids such as acetic acid, propionic acid, isbutyric acid, oxalic acid, maleic acid, malonic acid, benzoic acid, succinic acid, suberic acid, fumeric mandelic acid, phthalic acid, benzenesulfonic acid, p-tolylsulfonic acid, citric acid, tartaric acid, methanesulfonic acid, etc. Also included are salts of amino acids such as arginates, and salts of organic acids such as glucuronic acid or galactunoric acid (see, for example, Berge, SM, et al, "Pharmaceutical Salts", Journal of Pharmaceutical Science, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.
[0031] The neutral forms of the compounds can be registered by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for purposes of this invention.
[0032] In addition to salt forms, the present invention provides compounds in prodrug form. Prodrugs of the compounds described herein are compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Furthermore, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an ex vivo environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent. Prodrugs are often useful because in some situations they may be easier to administer than the parent drug. Prodrugs may be bioavailable by oral administration, whereas the parent drug is not. Prodrugs may also have improved solubility in pharmacological compositions over the parent drug. A wide variety of prodrug derivatives are known in the art, such as those that result from hydrolytic cleavage or oxidative activation of the prodrug. An example of a prodrug would be, but is not limited to, a compound of the present invention that is administered as an ester and then metabolically hydrolyzed to the carboxylic acid, which is the active entity. Additional examples include peptidyl derivatives of the compounds of the present invention.
[0033] Certain compounds of the present invention can exist in unsolvated and solvated forms, including hydrated forms. In general, solvated forms are equivalent to unsolvated forms and are intended to be included within the scope of the present invention. Certain compounds of the present invention can exist in polycrystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.
[0034] In a preferred embodiment, the compositions of the present invention may include a non-ionic surfactant, a viscosity increasing agent, preferably hydroxypropylmethylcellulose ("HPMC") or carboxymethylcellulose, a buffer, and optionally a sorbate.
[0035] Nonionic surfactants suitable for use in the present invention include, but are not limited to, polysorbates, poloxamers, polyoxyls, alkylaryl polyethers, cyclodextrins, tocopheryl polyethylene glycol succinates, glucosyl dialkyl ethers and crown ethers, ester-linked surfactants. Nonionic surfactants may be present in the compositions of the present invention at a concentration of about 1% to about 5% (w / v).
[0036] Polysorbates suitable for use in the present invention include, but are not limited to, polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) and polysorbate 80 (polyoxyethylene (20) sorbitan monooleate).
[0037] Polysorbate may be present in the compositions of the invention at a concentration of about 1% to about 5% (w / v), more preferably about 2% to about 3% (w / v), and most preferably about 2.5% (w / v).
[0038] Cyclodextrins suitable for use in the present invention include, but are not limited to, butyrate-containing or non-containing, ionically charged (e.g., anionic) beta cyclodextrin (Captisol®), 2-hydroxypropyl beta cyclodextrin ("HPβCD"), alpha cyclodextrin, and gamma cyclodextrin.
[0039] Poloxamers include, but are not limited to, poloxamer 103, poloxamer 123, and poloxamer 124, poloxamer 407, poloxamer 188, poloxamer 338, and any poloxamer analogs or derivatives.
[0040] Polyoxyls include, but are not limited to, Brij® 35, 78, 98, 700 (polyoxyethylene glycol alkyl ethers) and Spans (sorbitan esters) and Span® 20-80 (sorbitan monolaurate, sorbitan monopalmitate, sorbitan monostearate, and sorbitan monooleate).
[0041] The thickening agent, preferably HPMC, may be present in the compositions of the invention at a concentration of about 0.1% to about 1.2% (w / v), preferably about 1.2% (w / v).
[0042] Buffers useful in the present invention include, but are not limited to, citrate buffers and phosphate buffers. The buffers may be present in the compositions of the present invention at a concentration of about 1 millimolar ("mM") to about 10 mM, preferably about 2 mM to about 6 mM, and more preferably about 3 mM to about 4 mM.
[0043] The sorbate may be present in the composition of the present invention at a concentration of about 0.01% to about 0.5% (w / v), preferably about 0.05% to about 0.25% (w / v), and more preferably about 0.1% (w / v).
[0044] As used herein, all numerical values defined as "about" each particular value, pertaining to amounts, weights, etc., are plus or minus 10%. For example, the phrase "about 5% (w / v)" is to be understood as "4.5% to 5.5% (w / v)." Thus, amounts within 10% of the claimed value are encompassed by the claims.
[0045] As used herein, "% (w / v)" refers to the weight percentage of the total composition.
[0046] As used herein, the terms "subject" and "patient" are used interchangeably and refer to, but are not limited to, a human or other animal.
[0047] As used herein, the term "prevent" or "preventing" refers to keeping, diverting, removing, forestalling, stopping, or impeding something from happening, especially by a progressive effect.
[0048] As used herein, the term "treat" or "treating" refers to reversing, alleviating, or slowing the progression of the disease, disorder, or condition to which such term applies, or one or more symptoms of such disease, disorder, or condition.
[0049] As used herein, the term "administration" or "administering" refers to administration via topical application, injection or implant.
[0050] The articles "a," "an," and "the" are intended to include plural as well as singular, unless the context clearly indicates otherwise. Use in combination with glaucoma medications
[0051] The discovery of the present invention is that low concentrations of brimonidine, approximately one-fifth the concentration in currently available formulations in combination with a second glaucoma drug, can reduce intraocular pressure to a greater extent than the second glaucoma drug alone, while whitening the eye and greatly reducing and / or eliminating the recurrence of redness associated to date with brimonidine alone or in certain glaucoma drug combinations. Topical application of very low dose brimonidine ("ELDB") in combination with this second glaucoma drug demonstrates reductions in intraocular pressure that may be similar or better than full concentration brimonidine combinations and may be synergistic than either agent alone.
[0052] Furthermore, the main obstacle in treating glaucoma is patient compliance. Many patients discontinue administering glaucoma therapy due to the associated side effects, including conjunctival hyperemia and recurrence of hyperemia (i.e., red eye). The discovery of the present invention is that the use of ELDB in combination treats glaucoma while greatly reducing the side effects, such as conjunctival hyperemia, associated with full concentration brimonidine concentration. Finally, ELDB can whiten the sclera of the eye beyond the subject's baseline whiteness, which can lead to even greater patient compliance.
[0053] Without wishing to be bound by any particular theory, ELDB can reduce systemic delivery of glaucoma drugs, thus reducing systemic side effects, and can lead to greater retention of glaucoma drugs on the surface of the eye, which can lead to greater intraocular absorption of glaucoma drugs, thus reducing the amount and / or frequency of administration, leading to greater patient compliance.
[0054] In one embodiment, the present invention is directed to an ophthalmic composition for the treatment of glaucoma comprising brimonidine at a concentration of about 0.01% to about 0.050% (w / v) and a second glaucoma medication.
[0055] Brimonidine can be at a concentration of about 0.005% to about 0.050% (w / v), preferably about 0.005% to about 0.050% (w / v), about 0.01% to about 0.050% (w / v) about 0.025% to about 0.045% (w / v), about 0.025% to about 0.035% (w / v), and about 0.025%, about 0.035%, or about 0.04% (w / v).
[0056] Glaucoma drugs useful for the present invention other than brimonidine include, but are not limited to, prostaglandins, ROCK inhibitors, beta-blockers and carbonic anhydrase inhibitors ("CAIs"). Prostaglandins include, but are not limited to, latanoprost, bimatoprost, travaprost, tafluprost, and pharmaceutically acceptable salts thereof. Rho kinase inhibitors include, but are not limited to, netarsudil. Beta-blockers include, but are not limited to, carteolol, timoptic, timolol, betaloxol, levobunolol, metipranolol, and pharmaceutically acceptable salts thereof. CAIs include, but are not limited to, brinzolamide, dorzolamide, acetazolamide, methazolamide, and pharmaceutically acceptable salts thereof.
[0057] Glaucoma drugs other than brimonidine may be at a concentration of about 0.001% to about 5% (w / v). Preferably, prostaglandins are at a concentration of about 0.001% to about 0.1% (w / v), more preferably about 0.0015% to about 0.03% (w / v), beta blockers are at a concentration of about 0.1% to about 1% (w / v), more preferably about 0.25% to about 0.5% (w / v), rho kinase inhibitors are at a concentration of about 0.01% to about 1% (w / v), preferably about 0.01% to about 0.05% (w / v), and CAIs are at a concentration of about 0.5% to about 5% (w / v), more preferably about 1% to about 2% (w / v). Warm glaucoma drugs for ophthalmic administration are currently commercially available under the following concentrations of active ingredients: namely, 0.004% travaprost, 0.01% and 0.03% bimatoprost, 0.0015% tafluprost, 0.005% latanoprost, 0.02% netarsudil, 0.25% and 0.5% timolol maleate, 0.25% and 0.5% timolol hemihydrate, 0.25% and 0.5% betaxolol hydrochloride ("HCl"), 0.25% and 0.5% levobunolol HCl, 1% brinzolamide, and 2% dorzolamide.
[0058] Specific combinations of brimonidine and a second glaucoma medication include, but are not limited to, about 0.035% to 0.050% (w / v) brimonidine and about 0.005% (w / v) latanoprost, about 0.035% to 0.050% (w / v) brimonidine and about 0.050% (w / v) bimatoprost, about 0.035% to about 0.050% (w / v) brimonidine and about 0.5% (w / v) timolol, and about 0.035% to about 0.050% (w / v) brimonidine and about 2% (w / v) dorzolamide.
[0059] The compositions of the present invention may have a pH of about 5.0 to about 8.0 for brimonidine glaucoma concomitant medications, more preferably about 6.0 to about 7.5, even more preferably about 7.2 to about 7.7, and even more preferably about 7.4 to about 7.6.
[0060] In a preferred embodiment, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: Approximately 0.001% (w / v) latanoprost; About 0.050% (w / v) brimonidine; Approximately 2.5% (w / v) polysorbate; About 1.2% (w / v) hydroxypropyl methylcellulose ("HPMC"); About 5 mM boric acid, Optionally, about 0.1% (w / v) sorbate; wherein the composition has a pH of about 7.4.
[0061] Methocell® was used as the source of HPMC (Methocell is a registered trademark of and available from Dow Corning).
[0062] In another preferred embodiment, the present invention provides About 0.05% (w / v) timolol; About 0.050% (w / v) brimonidine; Approximately 2.5% (w / v) polysorbate; Approximately 1.2% (w / v) HPMC; About 4 mM boric acid, Optionally, about 0.1% (w / v) sorbate; wherein the composition has a pH of about 7.4.
[0063] The compositions of the present invention for the treatment of glaucoma can be administered to the eye locally, via intraocular injection or via an intraocular implant, preferably administration occurs via topical application. Use with histamine antagonists
[0064] Currently available antihistamines (i.e., histamine antagonists) are unable to completely alleviate all allergic symptoms, including red eye, particularly those associated with cytokine-induced vasodilation. The discovery of the present invention shows that the combination of an extremely low dose of brimonidine ("ELDB") with an antihistamine not only results in a greater reduction in redness than the use of an antihistamine alone, but also in greater relief of allergic symptoms, such as conjunctival swelling.
[0065] In one embodiment, the present invention is directed to an ophthalmic composition for the treatment of allergies comprising brimonidine at a concentration of about 0.005% to about 0.050% (w / v) and a histamine antagonist.
[0066] Brimonidine may be at a concentration of about 0.005% to about 0.050% (w / v), preferably about 0.01% to about 0.050% (w / v), more preferably about 0.025% to about 0.035% (w / v) and about 0.025%, about 0.035% or about 0.04% (w / v).
[0067] Histamine antagonists useful for the present invention include, but are not limited to, naphazoline, antazoline, azelastine, carbinoxamine, cyproheptadine, emedastine, hydroxyzine, levocabastine, brompheniramine, chlorpheniramine, clemastine, diphenhydramine, ketotifen, loratadine, desloratadine, cetirizine, fexofenadine, olopatadine, acrivastine, ebastine, norastemizole, levocetirizine, mizolastine, pheniramine, pharma- ceutically acceptable salts thereof, and combinations thereof.
[0068] The histamine antagonist may be at a concentration of about 0.01 to about 1% (w / v), preferably about 0.025% to about 0.7% (w / v). Histamine antagonists for nasal or ophthalmic administration are currently commercially available under the following concentrations of active ingredient: These include: 0.05% naphazoline HCl; 0.05% naphazoline HCl in combination with 0.5% antazoline phosphate; 0.05% naphazoline HCl in combination with 0.3% pheniramine maleate; 0.02675% naphazoline hydrochloride in combination with 0.315% pheniramine maleate; 0.1% and 0.15% azelastine; 0.05% emedastine; 0.05% levocabastine HCl; 0.025% ketotifen; and 0.1%, 0.2% and 0.7% olopatadine.
[0069] In a preferred embodiment, the present invention provides a method for producing a pharmaceutical composition comprising the steps of: About 0.0035% (w / v) ketotifen fumarate; About 0.035% (w / v) brimonidine; Approximately 2.5% (w / v) polysorbate; About 0.1% to about 1.2% (w / v) HPMC; About 4 mM citrate buffer; Optionally, about 0.1% (w / v) sorbate; wherein the composition has a pH of 6.5. Concomitant use with nonsteroidal anti-inflammatory drugs
[0070] Currently available nonsteroidal anti-inflammatory drugs ("NSAIDs") are unable to completely reduce all inflammation. The discovery of the present invention is that the combination of very low dose brimonidine ("ELDB") and NSAIDs leads to greater reduction in inflammation than the use of NSAIDs alone. Furthermore, there is significant inflammation, hyperemia and irritation that is widely known to be cytokine-induced, and the combination of low dose brimonidine and low concentration NSAIDs such as ketorolac 0.025% can provide both relief of hyperemia and reduction of inflammation. It is believed that this combination can improve the quality of life for those suffering from chronic ocular allergies better than either product alone.
[0071] In one embodiment, the present invention is directed to an ophthalmic composition for reducing inflammation comprising brimonidine at a concentration of about 0.005% to about 0.050% (w / v) and an NSAID.
[0072] Brimonidine may be at a concentration of about 0.005% to about 0.050% (w / v), preferably about 0.01% to about 0.050% (w / v), more preferably about 0.025% to about 0.035% (w / v) and about 0.025%, about 0.035% or about 0.04% (w / v).
[0073] NSAIDs useful for the present invention include, but are not limited to, ketorolac, aspirin, celecoxib, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, oxaprozin, salsalate, sulindac, tolmetin, and pharma- ceutically acceptable salts thereof, and combinations thereof.
[0074] The NSAID may be at a concentration of about 0.01% to about 10% (w / v), preferably about 0.01% to about 1% (w / v), and more preferably about 0.02% to about 0.50% (w / v).
[0075] The compositions of the present invention for reducing inflammation can be administered topically via drops or sprays to the eye or nasal passages. EXAMPLES
[0076] Example 1 - Predicted Reduction in Intraocular Pressure method Subjects with normal baseline intraocular pressure ("IOP", <21 mmHg) were prospectively treated for 5 consecutive days with a single dose of a composition containing 0.035% brimonidine, 0.005% latanoprost, and a combination of 0.03% brimonidine and 0.005% latanoprost, dropped twice a day per eye. A one-week washout period was observed between each of the three treatment cycles. Dosing was performed at 8:30 a.m., followed by punctual 30-second occlusions with dosing on days 1, 3, and 5.
[0077] IOP was measured at one or more of the following times: 4, 8, 12, 24, and 32 hours, and comfort and side effect profiles were assessed qualitatively.
[0078] result Based on the preliminary experimental data, the formulations of the present invention tested predictably achieved greater IOP reduction than latanoprost alone. Furthermore, peak IOP reduction effects were predictably achieved at approximately 4-8 hours post-dose, with IOP remaining below baseline for 24 hours post-dose. Figure 1 demonstrates predictive examples of IOP reduction following administration of 0.005% latanoprost (0 hours, white bars) versus IOP reduction following administration of 0.03% brimonidine and 0.005% latanoprost (4, 6, and 8 hours, black bars). In fact, IOP reduction following administration of ELDB in combination with latanoprost predictably achieved synergy at all times and days except pre-dose. Synergy would be calculated by observing the reduction in IOP and dividing by the predicted reduction in IOP to give a "synergy factor." A synergy factor greater than 1 demonstrates synergy. The expected IOP reduction will be calculated using the following formula, where A is the IOP reduction for ELDB alone and B is the IOP reduction for latanoprost alone. A+B-(AB / 100). Thus, the formulation of the present invention predictively demonstrates improved performance across all concentrations of brimonidine and latanoprost alone under similar test conditions. Finally, during latanoprost alone, subjects predictively experience ocular hyperemia that was not observed during the test of brimonidine or the combination of brimonidine and latanoprost, demonstrating that extremely low doses of brimonidine can not only enhance IOP reduction, but also reduce the associated side effects of glaucoma medication.
[0079] In conclusion, the combination of ELDB with a second glaucoma drug predictably provides enhanced and synergistic relief of intraocular pressure that is either as good or even better than that provided by the second glaucoma drug alone or in combination with full strength brimonidine. Additionally, the combination of ELDB with a second glaucoma drug predictably provides a reduction or amelioration of side effects that typically occur when the second glaucoma drug is administered alone.
[0080] Example 2 - Prediction: Allergy Relief method Subjects suffering from nasal allergy were prospectively administered a combination of 0.005% to 0.050% (w / v) brimonidine and either 0.025% to 0.035% (w / v) ketotifen fumarate or 0.3% (w / v) pheniramine maleate for 7 consecutive days.
[0081] result The formulations of the present invention tested predictively achieved greater reductions in cytokines and inflammation than ketotifen or pheniramine alone. Additionally, the formulations of the present invention tested predictively reduced the red eye associated with ketotifen and pheniramine. Finally, the formulations of the present invention tested predictively whitened the subjects' eyes beyond baseline whiteness.
Claims
1. 1. An ophthalmic composition for the treatment of glaucoma, comprising about 0.01% to about 0.050% (w / v) brimonidine and an effective amount of a second glaucoma drug, where (w / v) refers to weight by total volume of the composition.
2. 2. The composition of claim 1, wherein the brimonidine is at a concentration of about 0.035% to about 0.050% (w / v).
3. 2. The composition of claim 1, wherein the second glaucoma medication is selected from the group consisting of prostaglandins, beta blockers, rho kinase inhibitors, and carbonic anhydrase inhibitors.
4. 2. The composition of claim 1, wherein the glaucoma medication is selected from the group consisting of latanoprost, bimatoprost, travaprost, tafluprost, netarsudil, carteolol, timoptic, timolol, betaloxol, levobunolol, metipranolol, brinzolamide, dorzolamide, acetazolamide, methazolamide, and pharmaceutically acceptable salts thereof.
5. 10. The composition of claim 1, wherein the second glaucoma medication is at a concentration of about 0.001% to about 1.0% (w / v).
6. 4. The composition of claim 3, wherein the second glaucoma medication is a prostaglandin at a concentration of about 0.001% to about 0.1% (w / v), or a rho-kinase inhibitor at a concentration of about 0.01% to about 1.0% (w / v), or a beta-blocker at a concentration of about 0.1% to about 1.0% (w / v), or a carbonic anhydrase inhibitor at a concentration of about 0.5% to about 5% (w / v).
7. 4. The composition of claim 3, wherein the second glaucoma medication is a prostaglandin at a concentration of about 0.0015% to about 0.03% (w / v), a rho-kinase inhibitor at a concentration of about 0.01% to about 0.05% (w / v), a beta-blocker at a concentration of about 0.25% to about 0.5% (w / v), or a carbonic anhydrase inhibitor at a concentration of about 1% to about 2% (w / v).
8. 2. The composition of claim 1, wherein brimonidine is at a concentration of about 0.050% (w / v) and the second glaucoma drug is latanoprost at a concentration of about 0.005% (w / v).
9. 2. The composition of claim 1, wherein brimonidine is at a concentration of about 0.050% (w / v) and the second glaucoma drug is bimatoprost at a concentration of about 0.05% (w / v).
10. 2. The composition of claim 1, wherein brimonidine is at a concentration of about 0.050% (w / v) and the second glaucoma drug is timolol at a concentration of about 0.5% (w / v).
11. 2. The composition of claim 1, wherein brimonidine is at a concentration of about 0.04% (w / v) and the second glaucoma drug is dorzolamide at a concentration of about 2% (w / v).
12. 10. The composition of claim 1, further comprising a non-ionic surfactant, a thickening agent, a buffer, and optionally a sorbate.
13. The composition of claim 12, wherein the non-ionic surfactant is a polysorbate at a concentration of about 1% to about 5% (w / v).
14. A method of treating glaucoma comprising administering to a subject in need thereof the composition of claim 1.
15. 15. The method of claim 14, further providing reduced redness.
16. 15. The method of claim 14 further providing eye whitening.
17. 15. The method of claim 14, further providing reduced conjunctival swelling, reduced redness, eye whitening, or a combination thereof.
18. 1. An ophthalmic composition for the treatment of allergies comprising about 0.005% to about 0.050% brimonidine and an effective amount of a histamine antagonist, wherein (w / v) indicates weight by total volume of the composition.
19. 19. The composition of claim 18, wherein the brimonidine is at a concentration of about 0.025% to about 0.035% (w / v).
20. 19. The composition of claim 18, wherein the histamine antagonist is selected from the group consisting of naphazoline, antazoline, azelastine, carbinoxamine, cyproheptadine, emedastine, hydroxyzine, levocabastine, brompheniramine, chlorpheniramine, clemastine, diphenhydramine, ketotifen, loratadine, desloratadine, cetirizine, fexofenadine, olopatadine, acrivastine, ebastine, norastemizole, levocetirizine, mizolastine, pheniramine, pharmaceutically acceptable salts thereof, and combinations thereof.
21. 19. The composition of claim 18, wherein the histamine antagonist is at a concentration of about 0.025% to about 0.7% (w / v).
22. 20. The composition of claim 18, further comprising a non-ionic surfactant, hydroxypropyl methylcellulose, and a buffer, and optionally a sorbate.
23. 23. The composition of claim 22, wherein the non-ionic surfactant is a polysorbate at a concentration of about 1% to about 5% (w / v).
24. 20. A method of treating or preventing an allergic response comprising administering to a subject in need thereof a composition according to claim 16.
25. 25. The method of claim 24, further providing eye whitening.
26. 25. The method of claim 24, further providing selective vasoconstriction of small blood vessels, reduction in post-capillary venular leakage, reduction in cytokine, leukotriene-induced inflammation, or a combination thereof.
27. An ophthalmic composition for reducing inflammation comprising about 0.005% to about 0.050% (w / v) brimonidine and an effective amount of a nonsteroidal anti-inflammatory drug (NSAID), where (w / v) refers to weight by total volume of the composition.
28. 28. The composition of claim 27, wherein the brimonidine is at a concentration of about 0.025% to about 0.035% (w / v).
29. 28. The composition of claim 27, wherein the NSAID is selected from the group consisting of ketorolac, aspirin, celecoxib, diflunisal, etodolac, ibuprofen, indomethacin, ketoprofen, nabumetone, naproxen, oxaprozin, salsalate, sulindac, tolmetin, and pharma- ceutically acceptable salts thereof, and combinations thereof.
30. 30. The composition of claim 29, wherein the NSAID is ketorolac.
31. 28. The composition of claim 27, wherein the NSAID is at a concentration of about 0.02% to about 0.50% (w / v).
32. 28. The composition of claim 27, further comprising a non-ionic surfactant, a thickening agent, a buffer, and optionally a sorbate.
33. 33. The composition of claim 32, wherein the non-ionic surfactant is a polysorbate at a concentration of about 1% to about 5% (w / v).
34. 26. A method of reducing inflammation comprising administering to a subject in need thereof the composition of claim 25.
35. about 0.001% (w / v) latanoprost or 0.05% (w / v) timolol; About 0.050% (w / v) brimonidine; About 2.5% (w / v) polysorbate; About 1.2% (w / v) hydroxypropyl methylcellulose; containing about 5 millimolar boric acid; 1. A composition for the treatment of glaucoma, which may further comprise about 0.1% (w / v) sorbate, The composition has a pH of about 7.
4.
36. About 0.0035% (w / v) ketotifen fumarate; About 0.035% (w / v) brimonidine; About 2.5% (w / v) polysorbate; About 0.1% to about 1.2% (w / v) hydroxypropyl methylcellulose; containing about 4 millimolar citrate buffer, 1. A composition for the treatment of allergic conjunctivitis, which may further comprise about 0.1% (w / v) sorbate, The composition has a pH of about 6.5.
Citation Information
Patent Citations
Combination of brimonidine and timolol for topical ophthalmic use
JP2005523316A
Methods and ophthalmic devices used to treat eye allergies
JP2010504984A
Vasoconstrictive composition and method of use
JP2011529894A
Ophthalmic formulations of ketotifen and methods of use
JP2012520880A
Ophthalmic formulations and methods of use of cetirizine
JP2012520882A
